Jin-Hwan Han
Overview
Explore the profile of Jin-Hwan Han including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1068
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kang T, Lan X, Mi T, Chen H, Alli S, Lim S, et al.
Science
. 2024 Oct;
386(6718):eadl4492.
PMID: 39388542
Epigenetic reinforcement of T cell exhaustion is known to be a major barrier limiting T cell responses during immunotherapy. However, the core epigenetic regulators restricting antitumor immunity during prolonged antigen...
2.
Chernyak N, Bhagwat B, Naravula S, Chen Y, Solban N, Zhang F, et al.
J Med Chem
. 2024 Sep;
67(18):16222-16234.
PMID: 39235949
Toll-like receptor (TLR) activation converts immunologically inactive tumors into immunologically active tumors by activating tumor residing antigen-presenting cells and recruitment of cytotoxic T lymphocytes. Targeted immune agonists (TIAs) are antibody...
3.
Patel A, Willingham A, Cheng A, Tomazela D, Bowman E, Kofman E, et al.
J Med Chem
. 2024 Aug;
67(17):15756-15779.
PMID: 39172064
Toll-like receptors 7 and 8 are involved in modulating the adaptive and innate immune responses, and their activation has shown promise as a therapeutic strategy in the field of immuno-oncology....
4.
Chen Y, Zhou S, Pradhan K, Chernyak N, Kofman E, Zhang F, et al.
J Immunol Methods
. 2023 Sep;
522:113553.
PMID: 37661047
Targeted immune agonist (TIA) comprising a TLR7 agonist conjugated to tumor-targeting antibodies have been shown to induce potent anti-tumor responses in various preclinical models. However, the clinical proof-of-concept of a...
5.
King M, Yuan R, Chen J, Pradhan K, Sariol I, Li S, et al.
J Biol Chem
. 2023 Jan;
299(3):102902.
PMID: 36642178
The programmed cell death protein-1 (PD-1) is highly expressed on the surface of antigen-specific exhausted T cells and, upon interaction with its ligand PD-L1, can result in inhibition of the...
6.
Han J, Cai M, Grein J, Perera S, Wang H, Bigler M, et al.
Front Immunol
. 2020 Dec;
11:615755.
PMID: 33329611
[This corrects the article DOI: 10.3389/fimmu.2020.573405.].
7.
Han J, Cai M, Grein J, Perera S, Wang H, Bigler M, et al.
Front Immunol
. 2020 Oct;
11:573405.
PMID: 33117369
The molecule "T cell immunoreceptor with immunoglobulin and ITIM domain," or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of...
8.
Thapa M, Tedesco D, Gumber S, Elrod E, Han J, Kitchens W, et al.
J Immunol
. 2020 Apr;
204(12):3117-3128.
PMID: 32332110
Defects in biliary transport proteins, MDR3 in humans and Mdr2 in mice, can lead to a spectrum of cholestatic liver disorders. Although B cell disorders and the aberrant Ab production...
9.
McLeod R, Angagaw M, Baral T, Liu L, Moniz R, Laskey J, et al.
Oncotarget
. 2018 Oct;
9(77):34459-34470.
PMID: 30349641
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been reported to mediate both tumorigenic and anti-tumor effects . Blockade of the CEACAM1 signaling pathway has recently been implicated as a...
10.
Wieland A, Kamphorst A, Valanparambil R, Han J, Xu X, Choudhury B, et al.
Sci Immunol
. 2018 Sep;
3(27).
PMID: 30242080
Persistent viral infections can interfere with FcγR-mediated antibody effector functions by excessive immune complex (IC) formation, resulting in resistance to therapeutic FcγR-dependent antibodies. We and others have previously demonstrated that...